Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May 10:9:52.
doi: 10.1186/1741-7015-9-52.

Clinical trials for stem cell therapies

Alan Trounson  1 , Rahul G Thakar, Geoff Lomax, Don Gibbons
Affiliations
Review

Clinical trials for stem cell therapies

Alan Trounson et al. BMC Med. .

Abstract

In recent years, clinical trials with stem cells have taken the emerging field in many new directions. While numerous teams continue to refine and expand the role of bone marrow and cord blood stem cells for their vanguard uses in blood and immune disorders, many others are looking to expand the uses of the various types of stem cells found in bone marrow and cord blood, in particular mesenchymal stem cells, to uses beyond those that could be corrected by replacing cells in their own lineage. Early results from these trials have produced mixed results often showing minor or transitory improvements that may be attributed to extracellular factors. More research teams are accelerating the use of other types of adult stem cells, in particular neural stem cells for diseases where beneficial outcome could result from either in-lineage cell replacement or extracellular factors. At the same time, the first three trials using cells derived from pluripotent cells have begun.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Diseases being addressed using mesenchymal stem cells (MSC) for clinical trials (n = number of trials).
Figure 2
Figure 2
Mesenchymal stem cell (MSC) clinical trials by clinical phase (n = number of trials).
See this image and copyright information in PMC

References

    1. Trounson A. New perspectives in human stem cell therapeutic research. BMC Med. 2009;7:29. doi: 10.1186/1741-7015-7-29. - DOI - PMC - PubMed
    1. Yang WZ, Zhang Y, Wu F, Min WP, Minev B, Zhang M, Luo XL, Ramos F, Ichim TE, Riordan NH. et al.Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions. J Transl Med. 2010;8:75. doi: 10.1186/1479-5876-8-75. - DOI - PMC - PubMed
    1. Prasad VK, Kurtzberg J. Umbilical cord blood transplantation for non-malignant diseases. Bone Marrow Transplant. 2009;44(10):643–651. doi: 10.1038/bmt.2009.290. - DOI - PubMed
    1. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317. doi: 10.1080/14653240600855905. - DOI - PubMed
    1. Buja LM, Vela D. Immunologic and inflammatory reactions to exogenous stem cells implications for experimental studies and clinical trials for myocardial repair. J Am Coll Cardiol. 2010;56(21):1693–1700. doi: 10.1016/j.jacc.2010.06.041. - DOI - PubMed

MeSH terms